Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MYH11
REST API REST API
Homo sapiens
MYH11 is differentially expressed in 280 experiments: 176 organism parts: liver, prostate, ... (174 more);, 219 disease states: normal, prostate carcinoma, ... (217 more);, 82 cell types 223 cell lines 28 compound treatments and 78 other conditions.
Synonyms SMMHC, SMHC
Orthologs Q4JH16_BOVIN (Bos taurus)   MYH11_RAT (Rattus norvegicus)   myh11b (Danio rerio)   myh11a (Danio rerio)   Myh11 (Mus musculus)   MYH11_CHICK (Gallus gallus)   MYO1 (Saccharomyces cerevisiae)   zip (Drosophila melanogaster)   myh11 (Xenopus laevis)   MYH11 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, myosin complex, protein binding, structural constituent of muscle, metabolic process, motor activity, muscle myosin complex, smooth muscle contraction, calmodulin binding, ATP binding, axon guidance, myosin filament, muscle contraction, skeletal muscle myosin thick filament assembly, nucleotide binding, actin binding, smooth muscle contractile fiber, stress fiber, cardiac muscle fiber development, elastic fiber assembly, melanosome
InterPro Term Myosin_head_motor_dom, Myosin_N, Myosin_tail, IQ_motif_EF-hand-BS
UniProt Accession Q66K75, P35749, B1PS43, D2JYH7, Q3MIV8, Q3MNF0, Q3MNF1, Q68D89
Gene-Disease Assocation AORTIC ANEURYSM, FAMILIAL THORACIC 4; AAT4
Search EB-eye ENSG00000133392
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, ... (37 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (28 experiments)

Factor Value U/D Experiments
MDA-MB-231
2
E-TABM-420, E-MTAB-62
MCF-10A
2
E-TABM-420, E-GEOD-14990
primary culture
2
E-GEOD-2450, E-GEOD-1657
MCF-7
1
2
E-GEOD-3529, E-GEOD-19639, E-GEOD-20081
HeLa
1
2
E-MTAB-62, E-GEOD-5823, E-GEOD-20081
HMEC184
1
E-MEXP-1006
217 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-3920, E-GEOD-20677, E-GEOD-13987, E-TABM-34, ... (41 experiments)

Factor Value U/D Experiments
monocyte
3
E-GEOD-11755, E-GEOD-5099, E-MEXP-583
CD4+ T cell
2
E-MTAB-24, E-MTAB-25
fibroblast
2
E-GEOD-3920, E-GEOD-26672
stromal cell
1
2
E-MEXP-2034, E-MEXP-1327, E-GEOD-3998
ADC
1
1
E-GEOD-19188
platelet
1
E-GEOD-2006
76 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (74 experiments)

Factor Value U/D Experiments
prostate carcinoma
5
E-GEOD-96, E-GEOD-7307, E-MTAB-62, E-MEXP-2034, E-TABM-26 ... (5 experiments)
acute promyelocytic leukemia
4
E-MTAB-62, E-GEOD-96, E-GEOD-1729, E-GEOD-995
lung adenocarcinoma
4
E-MTAB-37, E-GEOD-2514, E-MTAB-62, E-MEXP-231
colon carcinoma
3
E-MTAB-57, E-GEOD-3726, E-MTAB-62
chronic myelogenous leukemia
2
E-GEOD-96, E-MTAB-62
AIDS-KS, HIV+, nodular (late) stage
2
2
E-MTAB-62, E-MEXP-66
213 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-15205, E-GEOD-5824, E-TABM-868, E-GEOD-5099, ... (18 experiments)

Factor Value U/D Experiments
none
3
4
E-GEOD-5824, E-MEXP-1958, E-GEOD-412, E-GEOD-5099, E-TABM-868, ... (7 experiments)
Cxcl12
1
1
E-GEOD-7307
actinomycin D
1
E-GEOD-6400
granulocyte macrophage-colony stimulating factor
1
E-GEOD-2803
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-MEXP-1269
TNF
1
E-GEOD-15205
22 more value(s).


A rna yield

studied in E-TABM-325

Factor Value U/D Experiments
113.86
1
1
E-TABM-325


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (11 experiments)

Clinical info
studied in E-GEOD-19743, E-MEXP-1251, E-GEOD-1563, E-GEOD-21589, E-GEOD-16363, ... (13 experiments)

Clinical treatment
studied in E-GEOD-5377, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-3140, E-GEOD-6236, E-GEOD-2666, ... (7 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-19665

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011

Genotype
studied in E-TABM-763, E-TABM-1029, E-GEOD-22056, E-GEOD-3494, E-GEOD-2466, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-MEXP-1446, E-GEOD-9764, E-MEXP-1103, ... (7 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MEXP-2069, E-GEOD-1926, E-TABM-26, E-GEOD-10433, ... (34 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, ... (6 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-TABM-130, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84 ... (5 experiments)

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-1309, E-GEOD-1493, E-GEOD-21750, E-GEOD-1657

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Qpcr egfr dct
studied in E-GEOD-5851

Qrt pcr ereg dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797

RNAi
studied in E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-11428

stimulus
studied in E-GEOD-22103

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-22152, E-GEOD-16837, E-GEOD-19246, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271, E-GEOD-3494, E-GEOD-4922

Tumor size
studied in E-GEOD-4922

Processing time: 0.534 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM